According
to the latest market report published by Transparency Market Research "Liver Diseases Therapeutics Market
(Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants)
- Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018",
the global liver diseases therapeutics market was worth USD 6.5 billion in 2011
and is expected to reach USD 10.9 billion in 2018, growing at a CAGR of 8.6%
from 2012 to 2018. In the overall global market, anti-viral drugs are expected
to create its lead position in terms of revenue generation by 2018. Anti-viral
drugs will have a share of 32.7% of the global market followed by vaccines at
19.1% in 2018.
Browse the Liver
Diseases Therapeutics Market full report at http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html
The
major drivers of the global liver disease therapeutics market are increasing
aging population inducing chronic diseases such as hepatitis and liver cancer,
increasing global prevalence of liver disorder, high unmet needs existing in
liver cancer and increased vaccination in emerging economies. However
side-effects and risks associated with the medication, strict FDA approval
norms and other government regulations and availability of alternate treatment
procedures may act as the barrier for this market. Strong pipeline drugs and
consolidation opportunities in the healthcare industry will pose future growth
prospect for this market.
Get Free Sample Report at http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=799
Anti-viral
drugs represent the largest market in the liver disease therapeutics, which is
justified by the fact that many oral, direct-acting antiviral medications are
in development phase for treating hepatitis C. Currently, anti-virals are only
available for hepatitis B and C. However, many anti-viral hepatitis C pipeline
drugs namely GS-7977 (Nucleoside/Nucleotide polymerase inhibitor), Daclatasvir
(NS5a Inhibitor), Asunaprevir (Protease Inhibitor), Simeprevie (Protease
Inhibitor), and Vaniprevir (Protease Inhibitor), are expected to accelerate
this market in near future.
Browse all Pharmaceutical Market Research Reports @
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
This
research is specially designed to estimate and analyze the demand for liver
diseases therapeutics in global market. The research provides an in-depth
analysis of the product sales, drugs class wise trend analysis and the major
player pertaining to this market. High level analysis of the mentioned drug
class of global liver diseases therapeutics market is performed and the report
provides detailed analysis, comprehensive historical data and statistically
tested forecast of the drug classes thus covered. Detailed qualitative
information is given for different liver diseases and the application of
different drugs as the treatment and therapy option.
0 comments:
Post a Comment